Preclinical Mechanisms of Topical PRN473, a Bruton Tyrosine Kinase Inhibitor, in Immune-Mediated Skin Disease Models

The expression of Bruton tyrosine kinase (BTK) in B cells and innate immune cells provides essential downstream signaling for BCR, Fc receptors, and other innate immune cell pathways. The topical covalent BTK inhibitor PRN473 has shown durable, reversible BTK occupancy with rapid on-rate and slow of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	ImmunoHorizons 2021-07, Vol.5 (7), p.581-589
Hauptverfasser:	Xing, Yan, Chu, Katherine A, Wadhwa, Jyoti, Chen, Wei, Zhu, Jiang, Bradshaw, J Michael, Shu, Jin, Foulke, Matthew C, Loewenstein, Natalie, Nunn, Philip, By, Kolbot, Phiasivongsa, Pasit, Goldstein, David M, Langrish, Claire L
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Cutaneous Administration, Oral Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors Animals Arthus Reaction - drug therapy Arthus Reaction - immunology Arthus Reaction - pathology Disease Models, Animal Dose-Response Relationship, Drug Drug Evaluation, Preclinical Female Humans Mice Passive Cutaneous Anaphylaxis - drug effects Protein Kinase Inhibitors - administration & dosage Rats Skin - drug effects Skin - immunology Skin - pathology Skin Diseases - drug therapy Skin Diseases - immunology Skin Diseases - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!